Marvel Biosciences Corp.
MRVL.V
TSX
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.69% | 10.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -52.62% | 128.04% | |||
| Operating Income | 52.62% | -128.04% | |||
| Income Before Tax | 47.00% | -67.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.00% | -67.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.00% | -67.66% | |||
| EBIT | 52.62% | -128.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 48.68% | -65.22% | |||
| Normalized Basic EPS | 50.00% | -71.43% | |||
| EPS Diluted | 48.68% | -65.22% | |||
| Normalized Diluted EPS | 50.00% | -71.43% | |||
| Average Basic Shares Outstanding | 4.33% | 0.01% | |||
| Average Diluted Shares Outstanding | 4.33% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||